Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

This article was originally published in The Pink Sheet Daily

Executive Summary

An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.

You may also be interested in...



Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs

FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.

Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs

FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.

FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients

Majority of the Oncologic Drugs Advisory Committee members support use in patients with progressive or symptomatic medullary thyroid cancer, a more limited indication than that proposed by the sponsor.

Related Content

Topics

UsernamePublicRestriction

Register

PS068667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel